{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-065723","form_type":"8-K","ticker":"NEUP","cik":"0001191070","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2025-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.505015+00:00","generated_at":"2026-05-18T05:35:44.219441+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Neuphoria receives Nasdaq deficiency notice for missing annual meeting; plans compliance plan","bullets":["Received Nasdaq notice on July 18, 2025 for failure to hold annual meeting within 12 months of fiscal year ended June 30, 2024.","Must submit compliance plan by September 1, 2025; if accepted, exception until December 29, 2025.","Company plans to hold 2025 annual meeting in November 2025, consistent with past practice.","Deficiency notice has no immediate impact on listing of NEUP common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-065723","json":"https://secwatch.observer/filing/0001213900-25-065723.json","markdown":"https://secwatch.observer/filing/0001213900-25-065723.md","text":"https://secwatch.observer/filing/0001213900-25-065723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/ea0249543-8k_neuphoria.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:35:44.219441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcb2eea891b943209c8e8653a504b30caa0b300f","claim":"Neuphoria Therapeutics Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).","evidence_excerpt":"July 18, 2025, Neuphoria Therapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s failure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001493152-26-025087","ticker":"LASE","company_name":"Laser Photonics Corp","filed_at":"2026-05-22T21:27:31+00:00","headline":"Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025087","json":"https://secwatch.observer/filing/0001493152-26-025087.json","markdown":"https://secwatch.observer/filing/0001493152-26-025087.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/0001493152-26-025087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 18, 2025, Neuphoria\nTherapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from\nthe Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company\nwas not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024.\nThe Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","comparable_excerpt":"received a notice from Nasdaq Listing Qualifications\ndepartment of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q\nfor the period ended March 31, 2026, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated\nthat the Company has 60 days to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception\nto allow the Company to regain compliance up to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or\nNovember 16, 2026. A\ncopy of t","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/0001493152-26-025087-index.htm"}},{"accession":"0002001557-26-000118","ticker":"INV","company_name":"Innventure, Inc.","filed_at":"2026-05-19T21:45:13+00:00","headline":"Innventure regains Nasdaq compliance after appointing Bruce Brown to Audit Committee","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002001557-26-000118","json":"https://secwatch.observer/filing/0002001557-26-000118.json","markdown":"https://secwatch.observer/filing/0002001557-26-000118.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2001557/000200155726000118/0002001557-26-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2001557/000200155726000118/innv-20260515.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 18, 2025, Neuphoria\nTherapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from\nthe Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company\nwas not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024.\nThe Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","comparable_excerpt":"April 30, 2026, following the resignation of Daniel Hennessy from the Company’s Board of Directors (the “Board”) and Audit Committee effective April 29, 2026, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) t","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2001557/000200155726000118/0002001557-26-000118-index.htm"}},{"accession":"0001213900-26-063806","ticker":"ILLR","company_name":"Triller Group Inc.","filed_at":"2026-06-02T12:26:59+00:00","headline":"Triller gets Nasdaq bid-price exception until June 30, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063806","json":"https://secwatch.observer/filing/0001213900-26-063806.json","markdown":"https://secwatch.observer/filing/0001213900-26-063806.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/ea0292925-8k_triller.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 18, 2025, Neuphoria\nTherapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from\nthe Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company\nwas not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024.\nThe Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","comparable_excerpt":"May 29, 2026, the Nasdaq Hearings Panel (the\n“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant\nTriller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,\n2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following\na successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which\nmodified a previous December 26, 2025 decision by a Nasdaq Hearings Panel","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm"}},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 18, 2025, Neuphoria\nTherapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from\nthe Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company\nwas not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024.\nThe Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001493152-26-026520","ticker":"NUTR","company_name":"NUSATRIP Inc","filed_at":"2026-06-01T11:10:27+00:00","headline":"NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026520","json":"https://secwatch.observer/filing/0001493152-26-026520.json","markdown":"https://secwatch.observer/filing/0001493152-26-026520.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 18, 2025, Neuphoria\nTherapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from\nthe Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company\nwas not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024.\nThe Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","comparable_excerpt":"May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”)\nfrom the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s\nnon-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely\nfile its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended\nMarch 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm"}},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 18, 2025, Neuphoria\nTherapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from\nthe Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company\nwas not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024.\nThe Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001683168-26-004399","ticker":"CSAI","company_name":"CLOUDASTRUCTURE, INC.","filed_at":"2026-05-29T21:09:11+00:00","headline":"Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004399","json":"https://secwatch.observer/filing/0001683168-26-004399.json","markdown":"https://secwatch.observer/filing/0001683168-26-004399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/cloud_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 18, 2025, Neuphoria\nTherapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from\nthe Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company\nwas not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024.\nThe Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","comparable_excerpt":"May 26, 2026, Cloudastructure,\nInc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq\nStock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for\nthe period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which\nrequires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional\ntime to review and confirm the accounting treatment for its outstand","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm"}},{"accession":"0001193805-26-000723","ticker":"GURE","company_name":"GULF RESOURCES, INC.","filed_at":"2026-05-29T20:45:30+00:00","headline":"Gulf Resources receives Nasdaq delisting notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory"],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000723","json":"https://secwatch.observer/filing/0001193805-26-000723.json","markdown":"https://secwatch.observer/filing/0001193805-26-000723.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/e665526_8k-gulfresources.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 18, 2025, Neuphoria\nTherapeutics Inc. (the “Company”) received a deficiency notification letter (the “ Notice ”) from\nthe Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”). The Notice indicated that the Company\nwas not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s\nfailure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024.\nThe Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025065723/0001213900-25-065723-index.htm","comparable_excerpt":"May 26, 2026, Gulf Resources\n(the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq\nStock Market LLC (“Nasdaq”), indicating that, as a result of not having timely filed its quarterly report on Form 10-Q for\nthe quarter ended March 31, 2026 (the “Form 10-Q”), and the Company remains delinquent in filing its annual report on Form\n10-K for the year ended December 31, 2025 (the “Initial Delinquent Filing”), the Company is in non-compliance with Nasdaq\nListing Rule 5250(c)(1), which requires timely filing all required periodic financial reports wit","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}